An update on the pharmacotherapy of neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 8, 2013, Pages 1017-1028

  Freund, K Bailey ^a,b,c   Mrejen, Sarah ^a,b,d   Gallego Pinazo, Roberto ^a,b,e  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Aflibercept; Age related macular degeneration; Anti angiogenic therapy; Bevacizumab; Choroidal neovascularization; Intravitreal injection; Pegaptanib sodium; Ranibizumab; VEGF; Verteporfin

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CYTOKINE RECEPTOR ANTAGONIST; DEXAMETHASONE; FOVISTA; LAMPALIZUMAB; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR ANTAGONIST; RANIBIZUMAB; SQUALAMINE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VERTEPORFIN;

BREAST CANCER; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SEROUS RETINOPATHY; CHRONIC DISEASE; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; ENDOPHTHALMITIS; GLIOBLASTOMA; GOLD STANDARD; HUMAN; INTRAOCULAR PRESSURE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; SYMPATHETIC OPHTHALMIA; TEMPORAL ARTERITIS; UVEITIS;

CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877651573     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.787410     Document Type: Review

References (91)

1. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39(5):367-74
2. D'Amico DJ. Diseases of the retina. N Engl J Med 1994;331(2):95-106
3. Coleman HR, Chan CC, Ferris FL III, Chew EY. Age-related macular degeneration. Lancet 2008;372(9652):1835-45
4. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122(4):477-85
5. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102(10):1450-60
6. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102(2):205-10
7. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119(10):1417-36
8. SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS report no. 22. Arch Ophthalmol 2007;125(9):1225-32
9. Biarnes M, Mones J, Alonso J, Arias L. Update on geographic atrophy in age-related macular degeneration. Optom Vis Sci 2011;88(7):881-9
10. Meleth AD, Wong WT, Chew EY. Treatment for atrophic macular degeneration. Curr Opin Ophthalmol 2011;22(3):190-3
11. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110(4):681-6
12. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110(2):259-66
13. Lee J, Freeman WR, Azen SP, et al. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: One-year results. Retina 2007;27(9):1205-13
14. Koff R, Rome S, Kasper R, et al. Subconjunctival injection of cortisone in iritis. J Am Med Assoc 1950;144(15):1259-60
15. Theodore FH. Use of cortisone in severe bilateral uveitis. Eye Ear Nose Throat Mon 1950;29(6):314-15
16. Baath J, Ells AL, Crichton A, et al. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007;23(3):304-10
17. Li Y, Chen H, Hou J, et al. Further characterization of ocular safety profile of commercially available preserved and preservative-free triamcinolone acetonide. Retina 2012;32(2):364-74
18. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14
19. Shimura M, Yasuda K, Nakazawa T, et al. Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema. Retina 2011;31(4):748-54
20. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127(9):1101-14
21. Ramezani A, Esfandiari H, Entezari M, et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2012;250(8):1149-60
22. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127(9):1115-28
23. Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Expert Opin Pharmacother 2009;10(15):2511-25
24. Kiernan DF, Mieler WF. Intraocular corticosteroids for posterior segment disease: 2012 update. Expert Opin Pharmacother 2012;13(12):1679-94
25. Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol 1994;59(3):328-35
26. Bakri SJ, Kaiser PK. Verteporfin ocular photodynamic therapy. Expert Opin Pharmacother 2004;5(1):195-203
27. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999;117(10):1329-45
28. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-Tap report 2. Arch Ophthalmol 2001;119(2):198-207
29. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131(5):541-60
30. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123(4):448-57
31. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: A nonrandomized clinical trial. Am J Ophthalmol 2010;149(2):307-15; e2
32. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110(8):1517-25
33. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112(2):301-4
34. Maberley D. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: A randomized clinical trial. Ophthalmology 2009;116(11):2149-57; e1
35. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-44
36. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65; e5
37. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
38. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study. Ophthalmology 2012;119(5):1001-10
39. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology 2012;119(5):992-1000
40. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: Verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27(2):133-40
41. Koh A, Lee WK, Chen LJ, et al. EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012;32(8):1453-64
42. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44(5):2155-62
43. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198(3):483-9
44. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: Differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004;45(2):368-74
45. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-16
46. Ahmadi MA, Lim JI. Pharmacotherapy of age-related macular degeneration. Expert Opin Pharmacother 2008;9(17):3045-52
47. Chakravarthy U, Staurenghi G, Kwok K, et al. Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age-related macular degeneration: Findings of the PERSPECTIVES study. Br J Ophthalmol 2012;96(10):1351-4
48. Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118(6):1107-18
49. Wroblewski JJ, Wells JA III, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009;127(4):374-80
50. Wroblewski JJ, Wells JA III, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol 2010;149(1):147-54
51. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146(4):508-12
52. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154(4):682-6; e2
53. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112(6):1035-47
54. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113(11):2002; e1-12
55. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36(4):331-5
56. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151(5):887-95; e1
57. Gonzalez S, Rosenfeld PJ, Stewart MW, et al. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012;153(2):196-203; e1
58. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119(7):1388-98
59. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
60. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411
61. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97(3):266-71
62. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27(9):1260-6
63. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27(5):536-44
64. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46(2):726-33
65. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32(3):434-57
66. Bolz M, Simader C, Ritter M, et al. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 2010;94(2):185-9
67. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1731-9
68. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4):566-83
69. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology 2011;118(4):663-71
70. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148(1):43-58; e1
71. Engelbert M, Zweifel SA, Freund KB. " ;Treat and extend" ; Dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/ retinal angiomatous proliferation. Retina 2009;29(10):1424-31
72. Engelbert M, Zweifel SA, Freund KB. Long-Term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified " ;treat and extend" ; Dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010;30(9):1368-75
73. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117(11):2134-40
74. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31(1):26-30
75. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: Multi-component, high-Affinity blockers of cytokine action. Nat Med 2003;9(1):47-52
76. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-8
77. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012;13(4):585-91
78. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep 2011;1(1):e5
79. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48
80. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: A game-changer or quiet addition? Am J Ophthalmol 2012;154(2):222-6
81. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond) 2009;23(9):1868-70
82. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168(6):2036-53
83. Binz HK, Stumpp MT, Forrer P, et al. Designing repeat proteins: Well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003;332(2):489-503
84. Campochiaro PA, Channa R, Berger BB, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase 1/2 study. Am J Ophthalmol 2012; [Epub ahead of print]
85. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: An integrated survey of emerging treatment alternatives. Retina 2010;30(9):1350-67
86. Connolly B, Desai A, Garcia CA, et al. Squalamine lactate for exudative age-related macular degeneration. Ophthalmol Clin North Am 2006;19(3):381-91, vi
87. 87. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010;30(9):1333-49
88. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994;118(3):285-98
89. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15(2):171-85
90. Vinores SA. Technology evaluation: Pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther 2003;5(6):673-9
91. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113(9):1508; e1-25